# Establishing Impurity Specifications for Antibiotics - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84

> FDA guidance document: Establishing Impurity Specifications for Antibiotics. Issue date: April 20, 2026. Get complete insights and analysis.

---

## Details

- Title: Establishing Impurity Specifications for Antibiotics
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2026-04-20
- Last Changed: 2026-04-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2025-D-6130">FDA-2025-D-6130</a>

## Related Documents

- [Data Integrity for In Vivo Bioavailability and Bioequivalence Studies](https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b)
- [Quality Considerations for Topical Ophthalmic Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/quality-considerations-for-topical-ophthalmic-drug-products/19494a43-f26e-42c9-b1ad-99a1126b3d42)
- [Benefit-Risk Considerations for Product Quality Assessments](https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-considerations-for-product-quality-assessments/dd4547d7-4ac9-437a-8d9b-b88b234da4bc)